{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:44:12Z","timestamp":1775515452261,"version":"3.50.1"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","award":["MRC-01\u201321\u2013472"],"award-info":[{"award-number":["MRC-01\u201321\u2013472"]}],"id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cell & Developmental Biology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.semcdb.2022.09.015","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T22:19:38Z","timestamp":1665181178000},"page":"239-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"PC","title":["The cross-talk between miRNAs and JAK\/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities"],"prefix":"10.1016","volume":"154","author":[{"given":"Kalyani","family":"Patil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulab","family":"Sher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Kuttikrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safwan","family":"Moton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Buddenkotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamir","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Steinhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahab","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcdb.2022.09.015_bib1","article-title":"Molecular pathogenesis of cutaneous T cell lymphoma: role of chemokines, cytokines, and dysregulated signaling pathways","author":"Patil","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"16","key":"10.1016\/j.semcdb.2022.09.015_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcdb.2022.09.015_bib3","unstructured":"E. Campo, Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., & Vardiman, J.W. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition, Volume 2 (2008) p. 439)."},{"key":"10.1016\/j.semcdb.2022.09.015_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hon.2584","article-title":"Cutaneous lymphomas-An update 2019","volume":"37 Suppl 1","author":"Kempf","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"23","key":"10.1016\/j.semcdb.2022.09.015_bib5","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1002\/cncr.27627","article-title":"Italiano Linfomi, Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas","volume":"118","author":"Quaglino","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.semcdb.2022.09.015_bib6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.clindermatol.2015.05.008","article-title":"Systemic involvement in mycosis fungoides","volume":"33","author":"Burg","year":"2015","journal-title":"Clin. Dermatol."},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.hoc.2018.09.001","article-title":"Mycosis fungoides and sezary syndrome: an update","volume":"33","author":"Larocca","year":"2019","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"5","key":"10.1016\/j.semcdb.2022.09.015_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcdb.2022.09.015_bib9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s41375-020-01068-2","article-title":"Xenograft and cell culture models of Sezary syndrome reveal cell of origin diversity and subclonal heterogeneity","volume":"35","author":"Poglio","year":"2021","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.semcdb.2022.09.015_bib10","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood.2019004725","article-title":"Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma","volume":"136","author":"Gaydosik","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.semcdb.2022.09.015_bib11","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-18-4099","article-title":"Clonotypic diversity of the T-cell receptor corroborates the immature precursor origin of cutaneous T-cell lymphoma","volume":"25","author":"Hamrouni","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"16","key":"10.1016\/j.semcdb.2022.09.015_bib12","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/bloodadvances.2018022608","article-title":"Single-cell heterogeneity in Sezary syndrome","volume":"2","author":"Buus","year":"2018","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.semcdb.2022.09.015_bib13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.4161\/cbt.12.12.18144","article-title":"The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma","volume":"12","author":"Abraham","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"Supplement 1","key":"10.1016\/j.semcdb.2022.09.015_bib14","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2018-99-119799","article-title":"Patricia Myskowski, Alison J. Moskowitz, Steven M. Horwitz, Ahmet Dogan, Mikhail Roshal;, Circulating lymphoma cells in mycosis fungoides\/Sezary syndrome show heterogeneity of the cell-of-origin and variable PD-1 expression by flow cytometric vnalysis","volume":"132","author":"Mariko Yabe","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.semcdb.2022.09.015_bib15","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/exd.13701","article-title":"Molecular pathogenesis of cutaneous lymphomas","volume":"27","author":"Stadler","year":"2018","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood.2019004256","article-title":"Genetic and epigenetic insights into cutaneous T-cell lymphoma","volume":"139","author":"Tensen","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semcdb.2022.09.015_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/wrna.121","article-title":"Posttranscriptional upregulation by microRNAs","volume":"3","author":"Vasudevan","year":"2012","journal-title":"Wiley Inter. Rev. RNA"},{"key":"10.1016\/j.semcdb.2022.09.015_bib18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of microRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O'Brien","year":"2018","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"4","key":"10.1016\/j.semcdb.2022.09.015_bib19","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/nar\/gki200","article-title":"Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis","volume":"33","author":"Cheng","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.semcdb.2022.09.015_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fgene.2012.00191","article-title":"miRNAs regulate stem cell self-renewal and differentiation","volume":"3","author":"Yu","year":"2012","journal-title":"Front Genet"},{"key":"10.1016\/j.semcdb.2022.09.015_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.conb.2017.02.014","article-title":"miRNAs in synapse development and synaptic plasticity","volume":"45","author":"Hu","year":"2017","journal-title":"Curr. Opin. Neurobiol."},{"issue":"4","key":"10.1016\/j.semcdb.2022.09.015_bib22","article-title":"MicroRNA-mediated regulatory circuits: outlook and perspectives","volume":"14","author":"Cora","year":"2017","journal-title":"Phys. Biol."},{"issue":"9","key":"10.1016\/j.semcdb.2022.09.015_bib23","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"16","key":"10.1016\/j.semcdb.2022.09.015_bib24","doi-asserted-by":"crossref","first-page":"R762","DOI":"10.1016\/j.cub.2014.06.043","article-title":"Aberrant regulation and function of microRNAs in cancer","volume":"24","author":"Adams","year":"2014","journal-title":"Curr. Biol."},{"issue":"10","key":"10.1016\/j.semcdb.2022.09.015_bib25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrg2634","article-title":"Causes and consequences of microRNA dysregulation in cancer","volume":"10","author":"Croce","year":"2009","journal-title":"Nat. Rev. Genet"},{"issue":"9","key":"10.1016\/j.semcdb.2022.09.015_bib26","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.jid.2018.03.1500","article-title":"MicroRNA signatures in diagnosis and prognosis of cutaneous T-cell lymphoma","volume":"138","author":"Shen","year":"2018","journal-title":"J. Invest Dermatol."},{"issue":"22","key":"10.1016\/j.semcdb.2022.09.015_bib27","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1182\/blood-2011-06-358382","article-title":"Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)","volume":"118","author":"Ralfkiaer","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcdb.2022.09.015_bib28","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/jid.2014.487","article-title":"MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma","volume":"135","author":"Sandoval","year":"2015","journal-title":"J. Invest Dermatol."},{"issue":"10","key":"10.1016\/j.semcdb.2022.09.015_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102136","article-title":"Plasma miR-155, miR-203, and miR-205 are biomarkers for monitoring of primary cutaneous T-cell lymphomas","volume":"18","author":"Dusilkova","year":"2017","journal-title":"Int J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.semcdb.2022.09.015_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224305","article-title":"Potential role for microRNA-16 (miR-16) and microRNA-93 (miR-93) in diagnosis and prediction of disease progression in mycosis fungoides in Egyptian patients","volume":"14","author":"Talaat","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.semcdb.2022.09.015_bib31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2017-06-788950","article-title":"Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study","volume":"131","author":"Lindahl","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semcdb.2022.09.015_bib32","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s12253-015-9897-8","article-title":"Altered microRNA expression in folliculotropic and transformed mycosis fungoides","volume":"21","author":"Marosvari","year":"2015","journal-title":"Pathol. Oncol. Res"},{"issue":"11","key":"10.1016\/j.semcdb.2022.09.015_bib33","doi-asserted-by":"crossref","first-page":"14667","DOI":"10.1007\/s13277-016-5325-2","article-title":"Aberrant microRNA expression in tumor mycosis fungoides","volume":"37","author":"Papadavid","year":"2016","journal-title":"Tumour Biol."},{"issue":"5","key":"10.1016\/j.semcdb.2022.09.015_bib34","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/jid.2011.481","article-title":"Deep-sequencing analysis reveals that the miR-199a2\/214 cluster within DNM3os represents the vast majority of aberrantly expressed microRNAs in Sezary syndrome","volume":"132","author":"Qin","year":"2012","journal-title":"J. Invest Dermatol."},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/nar\/gkn920","article-title":"Twist-1 regulates the miR-199a\/214 cluster during development","volume":"37","author":"Lee","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.semcdb.2022.09.015_bib36","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood-2009-12-256719","article-title":"MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential","volume":"116","author":"Ballabio","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semcdb.2022.09.015_bib37","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1038\/jid.2015.328","article-title":"Notch1 pathway activation results from the epigenetic abrogation of notch-related MicroRNAs in mycosis fungoides","volume":"135","author":"Gallardo","year":"2015","journal-title":"J. Invest Dermatol."},{"issue":"10","key":"10.1016\/j.semcdb.2022.09.015_bib38","doi-asserted-by":"crossref","first-page":"13637","DOI":"10.1007\/s13277-016-5259-8","article-title":"Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides","volume":"37","author":"Garaicoa","year":"2016","journal-title":"Tumour Biol."},{"issue":"9","key":"10.1016\/j.semcdb.2022.09.015_bib39","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jdv.15652","article-title":"Low Drosha protein expression in cutaneous T-cell lymphoma is associated with worse disease outcome","volume":"33","author":"Gambichler","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.semcdb.2022.09.015_bib40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jdermsci.2011.08.011","article-title":"High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas","volume":"64","author":"Valencak","year":"2011","journal-title":"J. Dermatol. Sci."},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1582-4934.2008.00556.x","article-title":"miR-21: a small multi-faceted RNA","volume":"13","author":"Krichevsky","year":"2009","journal-title":"J. Cell Mol. Med"},{"issue":"3","key":"10.1016\/j.semcdb.2022.09.015_bib42","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/jid.2010.349","article-title":"MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sezary syndrome","volume":"131","author":"van der Fits","year":"2011","journal-title":"J. Invest Dermatol."},{"issue":"29","key":"10.1016\/j.semcdb.2022.09.015_bib43","doi-asserted-by":"crossref","first-page":"45730","DOI":"10.18632\/oncotarget.10160","article-title":"STAT5 induces miR-21 expression in cutaneous T cell lymphoma","volume":"7","author":"Lindahl","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.immuni.2015.04.022","article-title":"A single miRNA-mRNA interaction affects the immune response in a context- and cell-type-specific manner","volume":"43","author":"Lu","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib45","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/imr.12057","article-title":"miR-155: an ancient regulator of the immune system","volume":"253","author":"Vigorito","year":"2013","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.semcdb.2022.09.015_bib46","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.immuni.2007.10.009","article-title":"microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells","volume":"27","author":"Vigorito","year":"2007","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.semcdb.2022.09.015_bib47","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.4161\/cc.24987","article-title":"STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma","volume":"12","author":"Kopp","year":"2013","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.semcdb.2022.09.015_bib48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/exd.12161","article-title":"miR-155 is involved in tumor progression of mycosis fungoides","volume":"22","author":"Moyal","year":"2013","journal-title":"Exp. Dermatol."},{"issue":"8","key":"10.1016\/j.semcdb.2022.09.015_bib49","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jid.2018.03.1526","article-title":"SATB1 in Malignant T Cells","volume":"138","author":"Fredholm","year":"2018","journal-title":"J. Invest Dermatol."},{"issue":"3","key":"10.1016\/j.semcdb.2022.09.015_bib50","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/cr.2011.144","article-title":"Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms","volume":"22","author":"Qin","year":"2012","journal-title":"Cell Res"},{"issue":"8","key":"10.1016\/j.semcdb.2022.09.015_bib52","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/jid.2015.116","article-title":"Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome","volume":"135","author":"Wong","year":"2015","journal-title":"J. Invest Dermatol."},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00403-016-1698-8","article-title":"CD164 identifies CD4(+) T cells highly expressing genes associated with malignancy in Sezary syndrome: the Sezary signature genes, FCRL3, Tox, and miR-214","volume":"309","author":"Benoit","year":"2017","journal-title":"Arch. Dermatol. Res"},{"issue":"9","key":"10.1016\/j.semcdb.2022.09.015_bib54","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.jid.2019.01.033","article-title":"Preclinical targeting of microRNA-214 in cutaneous T-cell lymphoma","volume":"139","author":"Kohnken","year":"2019","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.semcdb.2022.09.015_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.32","article-title":"MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome","volume":"2","author":"Narducci","year":"2011","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.semcdb.2022.09.015_bib56","doi-asserted-by":"crossref","first-page":"990","DOI":"10.4049\/jimmunol.1000793","article-title":"Costimulation-dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten","volume":"185","author":"Jindra","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcdb.2022.09.015_bib57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2016.11.010","article-title":"MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sezary syndrome patients","volume":"52","author":"Kohnken","year":"2017","journal-title":"Leuk. Res"},{"issue":"2","key":"10.1016\/j.semcdb.2022.09.015_bib58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/15384101.2016.1261226","article-title":"Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells","volume":"16","author":"Kodigepalli","year":"2017","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.semcdb.2022.09.015_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198477","article-title":"Mycosis fungoides progression could be regulated by microRNAs","volume":"13","author":"Manso","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.semcdb.2022.09.015_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002855","article-title":"Modulating the strength and threshold of NOTCH oncogenic signals by mir-181a-1\/b-1","volume":"8","author":"Fragoso","year":"2012","journal-title":"PLoS Genet"},{"issue":"14","key":"10.1016\/j.semcdb.2022.09.015_bib61","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/15384101.2019.1629789","article-title":"miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway","volume":"18","author":"Xia","year":"2019","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.semcdb.2022.09.015_bib62","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2013-09-527739","article-title":"MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma","volume":"123","author":"Ito","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semcdb.2022.09.015_bib63","first-page":"2361","article-title":"miRNA135a regulates Hut78 cell proliferation via the GATA3\/TOX signaling pathway","volume":"19","author":"Wei","year":"2019","journal-title":"Mol. Med Rep."},{"issue":"4","key":"10.1016\/j.semcdb.2022.09.015_bib64","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/jid.2013.461","article-title":"miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides\/cutaneous T-cell lymphoma","volume":"134","author":"McGirt","year":"2014","journal-title":"J. Invest Dermatol."},{"issue":"24","key":"10.1016\/j.semcdb.2022.09.015_bib65","doi-asserted-by":"crossref","first-page":"20555","DOI":"10.18632\/oncotarget.4111","article-title":"Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma","volume":"6","author":"Sibbesen","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.semcdb.2022.09.015_bib66","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/156652412799218886","article-title":"Emerging roles of microRNA-22 in human disease and normal physiology","volume":"12","author":"Xiong","year":"2012","journal-title":"Curr. Mol. Med"},{"issue":"28","key":"10.1016\/j.semcdb.2022.09.015_bib67","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1038\/onc.2015.435","article-title":"MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas","volume":"35","author":"Kitadate","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib68","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.semcdb.2022.09.015_bib69","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.3389\/fimmu.2019.02590","article-title":"JAK\/STAT cytokine signaling at the crossroad of NK cell Development and maturation","volume":"10","author":"Gotthardt","year":"2019","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.semcdb.2022.09.015_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT signaling: a double-edged sword of Immune regulation and cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.semcdb.2022.09.015_bib71","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat. Genet"},{"issue":"2","key":"10.1016\/j.semcdb.2022.09.015_bib72","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","article-title":"JAK2 inhibitors for myeloproliferative neoplasms: what is next?","volume":"130","author":"Bose","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcdb.2022.09.015_bib73","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-319-91439-8_6","article-title":"Ruxolitinib","volume":"212","author":"Ajayi","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.semcdb.2022.09.015_bib74","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-018-0060-z","article-title":"Phase II study of ruxolitinib, a selective JAK1\/2 inhibitor, in patients with metastatic triple-negative breast cancer","volume":"4","author":"Stover","year":"2018","journal-title":"NPJ Breast Cancer"},{"issue":"15","key":"10.1016\/j.semcdb.2022.09.015_bib75","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcdb.2022.09.015_bib76","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"Casteele, JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib77","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.semcdb.2022.09.015_bib78","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3324\/haematol.2015.132142","article-title":"JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications","volume":"100","author":"Springuel","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.semcdb.2022.09.015_bib79","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2008.08.008","article-title":"Canonical and non-canonical JAK-STAT signaling","volume":"18","author":"Li","year":"2008","journal-title":"Trends Cell Biol."},{"issue":"4","key":"10.1016\/j.semcdb.2022.09.015_bib80","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/ncb1713","article-title":"Drosophila STAT is required for directly maintaining HP1 localization and heterochromatin stability","volume":"10","author":"Shi","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"9","key":"10.1016\/j.semcdb.2022.09.015_bib81","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/ng1860","article-title":"JAK signaling globally counteracts heterochromatic gene silencing","volume":"38","author":"Shi","year":"2006","journal-title":"Nat. Genet"},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib82","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease","volume":"194","author":"Villarino","year":"2015","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib83","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.immuni.2010.07.001","article-title":"Nonconventional initiation complex assembly by STAT and NF-kappaB transcription factors regulates nitric oxide synthase expression","volume":"33","author":"Farlik","year":"2010","journal-title":"Immunity"},{"issue":"5351","key":"10.1016\/j.semcdb.2022.09.015_bib84","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1126\/science.279.5351.703","article-title":"Transcription factor-specific requirements for coactivators and their acetyltransferase functions","volume":"279","author":"Korzus","year":"1998","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.semcdb.2022.09.015_bib85","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/ni.2712","article-title":"Expression and regulation of intergenic long noncoding RNAs during T cell development and differentiation","volume":"14","author":"Hu","year":"2013","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.semcdb.2022.09.015_bib86","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.immuni.2010.05.009","article-title":"Regulation of microRNA expression and abundance during lymphopoiesis","volume":"32","author":"Kuchen","year":"2010","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.semcdb.2022.09.015_bib87","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.cell.2013.01.015","article-title":"The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-gamma locus","volume":"152","author":"Gomez","year":"2013","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.semcdb.2022.09.015_bib88","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.4049\/jimmunol.1200774","article-title":"Cutting edge: influence of Tmevpg1, a long intergenic noncoding RNA, on the expression of Ifng by Th1 cells","volume":"189","author":"Collier","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcdb.2022.09.015_bib89","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.3389\/fimmu.2018.03012","article-title":"The multifaceted interface between cytokines and microRNAs: an ancient mechanism to regulate the good and the bad of inflammation","volume":"9","author":"Garavelli","year":"2018","journal-title":"Front Immunol."},{"issue":"21","key":"10.1016\/j.semcdb.2022.09.015_bib90","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.semcdb.2022.09.015_bib91","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/1541-7786.MCR-15-0399","article-title":"miR-155 overexpression promotes genomic instability by reducing high-fidelity polymerase delta expression and activating error-prone DSB repair","volume":"14","author":"Czochor","year":"2016","journal-title":"Mol. Cancer Res"},{"issue":"102","key":"10.1016\/j.semcdb.2022.09.015_bib92","doi-asserted-by":"crossref","first-page":"37647","DOI":"10.18632\/oncotarget.26479","article-title":"A study of meiomitosis and novel pathways of genomic instability in cutaneous T-cell lymphomas (CTCL)","volume":"9","author":"Tsang","year":"2018","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.semcdb.2022.09.015_bib93","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/1078-0432.CCR-15-1784","article-title":"STAT3\/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides","volume":"22","author":"Vieyra-Garcia","year":"2016","journal-title":"Clin. Cancer Res"},{"issue":"10","key":"10.1016\/j.semcdb.2022.09.015_bib94","first-page":"5277","article-title":"STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides","volume":"34","author":"Fredholm","year":"2014","journal-title":"Anticancer Res"},{"issue":"18","key":"10.1016\/j.semcdb.2022.09.015_bib95","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.4161\/15384101.2014.947759","article-title":"Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines","volume":"13","author":"Litvinov","year":"2014","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.semcdb.2022.09.015_bib96","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.4049\/jimmunol.163.7.4073","article-title":"Depressed IL-12-mediated signal transduction in T cells from patients with Sezary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4","volume":"163","author":"Showe","year":"1999","journal-title":"J. Immunol."},{"issue":"3 Pt A","key":"10.1016\/j.semcdb.2022.09.015_bib97","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2021.08.447","article-title":"MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma","volume":"142","author":"Han","year":"2022","journal-title":"J. Invest Dermatol."},{"issue":"7","key":"10.1016\/j.semcdb.2022.09.015_bib98","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.leu.2403385","article-title":"In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3","volume":"18","author":"Sommer","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.semcdb.2022.09.015_bib99","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/leu.2011.198","article-title":"Constitutive activation of STAT3 in Sezary syndrome is independent of SHP-1","volume":"26","author":"McKenzie","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.semcdb.2022.09.015_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122692","article-title":"Epigenetic silencing of tumor suppressor miR-124 directly supports STAT3 activation in cutaneous T-cell lymphoma","volume":"9","author":"Garcia-Colmenero","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.semcdb.2022.09.015_bib101","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0002-9440(10)64629-9","article-title":"Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter","volume":"157","author":"Zhang","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"15_suppl","key":"10.1016\/j.semcdb.2022.09.015_bib102","article-title":"Pierluigi Porcu, Youn H. Kim, Theresa Pacheco, Ahmad Sami Halwani et al., Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL)","volume":"35","author":"Francine","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcdb.2022.09.015_bib103","unstructured":"Cobomarsen received orphan drug designation from the U.S. FDA for the treatment of T-cell lymphoma (2022). Retrieved on 5th April 2022 from \u3008http:\/\/investors.miragen.com\/press-releases\/press-release\/2020\/Cobomarsen-Receives-Orphan-Drug-Designation-From-the-U.S.-FDA-for-the-Treatment-of-T-cell-Lymphoma\/default.aspx\u3009."},{"key":"10.1016\/j.semcdb.2022.09.015_bib104","unstructured":"miRagen announces internal review of preliminary topline data for the phase 2 SOLAR clinical trial of cobomarsen in patients with cutaneous T-cell lymphoma (CTCL)miRagen decides to discontinue further internal development of cobomarsen (2020). Retrieved on 5th April 2022 from \u3008http:\/\/investors.miragen.com\/press-releases\/press-release\/2020\/miRagen-Announces-Internal-Review-of-Preliminary-Topline-Data-for-the-Phase-2-SOLAR-Clinical-Trial-of-Cobomarsen-in-Patients-with-Cutaneous-T-Cell-Lymphoma-CTCL\/default.aspx\u3009, (2020)."},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Disco"},{"issue":"11","key":"10.1016\/j.semcdb.2022.09.015_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112611","article-title":"Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?","volume":"13","author":"Klein","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semcdb.2022.09.015_bib107","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112123","article-title":"Durable responses observed with JAK inhibition in T-cell lymphomas","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.semcdb.2022.09.015_bib108","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"37","key":"10.1016\/j.semcdb.2022.09.015_bib109","doi-asserted-by":"crossref","first-page":"40141","DOI":"10.18632\/oncotarget.5653","article-title":"The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells","volume":"6","author":"Mazzacurati","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.semcdb.2022.09.015_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248298","article-title":"Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma","volume":"16","author":"Karagianni","year":"2021","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.semcdb.2022.09.015_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14041070","article-title":"Combination of resminostat with ruxolitinib exerts antitumor effects in the chick embryo chorioallantoic membrane model for cutaneous T cell lymphoma","volume":"14","author":"Karagianni","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"61","key":"10.1016\/j.semcdb.2022.09.015_bib112","doi-asserted-by":"crossref","first-page":"103797","DOI":"10.18632\/oncotarget.21951","article-title":"Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases","volume":"8","author":"Civallero","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.semcdb.2022.09.015_bib113","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdermsci.2020.01.013","article-title":"The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway","volume":"97","author":"Li","year":"2020","journal-title":"J. Dermatol. Sci."},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib114","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ajh.24233","article-title":"Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Wilcox","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.semcdb.2022.09.015_bib115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2174\/1871520617666170327115657","article-title":"ECPIRM, a potential therapeutic agent for cutaneous T-cell lymphoma, inhibits cell proliferation and promotes apoptosis via a JAK\/STAT pathway","volume":"18","author":"Yang","year":"2018","journal-title":"Anticancer Agents Med Chem."},{"issue":"1","key":"10.1016\/j.semcdb.2022.09.015_bib116","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.15778","article-title":"Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions","volume":"185","author":"Lees","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcdb.2022.09.015_bib117","article-title":"Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations","author":"Ren","year":"2022","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.semcdb.2022.09.015_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051229","article-title":"MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas","volume":"12","author":"Gluud","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.semcdb.2022.09.015_bib119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059390","article-title":"cMyc\/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas","volume":"8","author":"Manfe","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.semcdb.2022.09.015_bib120","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/bjd.17425","article-title":"Unilesional mycosis fungoides is associated with increased expression of microRNA-17\u201392 and T helper 1 skewing","volume":"180","author":"Moyal","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.semcdb.2022.09.015_bib121","first-page":"7207","article-title":"MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma","volume":"34","author":"Ralfkiaer","year":"2014","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.semcdb.2022.09.015_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111711","article-title":"STAT3 dysregulation in mature T and NK cell lymphomas","volume":"11","author":"Seffens","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.semcdb.2022.09.015_bib123","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2017-09-805663","article-title":"Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma","volume":"131","author":"Kohnken","year":"2018","journal-title":"Blood"}],"container-title":["Seminars in Cell & Developmental Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1084952122002877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1084952122002877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:23:48Z","timestamp":1761067428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1084952122002877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":123,"alternative-id":["S1084952122002877"],"URL":"https:\/\/doi.org\/10.1016\/j.semcdb.2022.09.015","relation":{},"ISSN":["1084-9521"],"issn-type":[{"value":"1084-9521","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cross-talk between miRNAs and JAK\/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cell & Developmental Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcdb.2022.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}